Search Result

Isoforms Recommended:	CDK9

Results for "

CDK9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (221) AAK1 (1) Amyloid-β (1) Androgen Receptor (1) Antibiotic (2) Apoptosis (73) Atg8/LC3 (1) ATTECs (1) Aurora Kinase (2) Autophagy (2) Bcl-2 Family (11) BCL6 (1) Biochemical Assay Reagents (1) c-Myc (13) Casein Kinase (2) Caspase (6) Cholinesterase (ChE) (1) CMV (5) COX (1) DNA/RNA Synthesis (14) Dopamine Transporter (2) Drug Intermediate (1) Drug Isomer (4) DYRK (2) E3 Ligase Ligand-Linker Conjugates (5) EGFR (5) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (1) FGFR (1) FLT3 (4) Fungal (2) GSK-3 (6) HDAC (3) Histone Methyltransferase (1) HIV (8) HSV (2) IAP (2) Interleukin Related (1) IRAK (2) IRE1 (2) Isotope-Labeled Compounds (1) Itk (1) JAK (3) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (11) MAP4K (1) MEK (2) MELK (1) Molecular Glues (3) NEKs (2) p38 MAPK (1) PARP (6) PKC (1) PROTACs (24) Reactive Oxygen Species (ROS) (3) Reference Standards (16) SARS-CoV (2) Small Interfering RNA (siRNA) (3) STAT (1) Target Protein Ligand-Linker Conjugates (2) ULK (1) Virus Protease (1) Wee1 (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (215) Endocrinology (1) Infection (16) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (6)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

243

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12214A

NVP-2 40+ Cited Publications	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

HY-13461

PHA-767491 4 Publications Verification CAY10572	CDK	Cancer
PHA-767491 is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

HY-103628

*PROTAC CDK9* Degrader-1** 2 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and *CDK* as a selective *CDK9* degrader.

HY-173523

*KI-CDK9d-32*	PROTACs CDK c-Myc	Cancer
KI-CDK9d-32 is a highly selective and potent *CDK9* PROTAC degrader (DC₅₀: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .

HY-137478

KB-0742 3 Publications Verification	CDK	Cancer
KB-0742 is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .

HY-124639

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

HY-112811

*PROTAC CDK9* degrader-2**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compound 11c) is a potent and selective *CDK9* degrader based on PROTAC, with an IC₅₀ of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC .

HY-137478A

KB-0742 dihydrochloride 3 Publications Verification	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

HY-162919

YK-2168	CDK Apoptosis c-Myc	Cancer
YK-2168 is a potent and selective *CDK9* inhibitor with an IC50 of 5.9 nM. YK-2168 inhibits phosphorylation of the CDK9 substrate pS2-RNA Pol II C-terminal domain. YK-2168 induces apoptosis in tumor cells, suppresses expression of CDK9-regulated genes including MYC and Mcl1, and inhibits tumor growth in CDX mice models. YK-2168 can be used for the research of cancer, such as leukemia .

HY-12871B

Atuveciclib 5+ Cited Publications BAY-1143572	CDK	Cancer
Atuveciclib (BAY-1143572) is a potent and highly selective, oral *PTEFb/CDK9* inhibitor. Atuveciclib (BAY-1143572) inhibits *CDK9/CycT1* with an IC₅₀ of 13 nM .

HY-12871

Atuveciclib Racemate 1 Publications Verification BAY-1143572 Racemate	CDK	Cancer
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral *P-TEFb/CDK9* inhibitor which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-143584

AZ5576	CDK Apoptosis	Cancer
AZ5576 is a potent and highly selective *CDK9* inhibitor (IC₅₀: <5 nM). AZ5576 inhibits the phosphorylation of RNA polymerase II at Ser2, thereby inhibiting transcriptional elongation. AZ5576 can be used for hematological Malignancy research .

HY-13461A

PHA-767491 hydrochloride 4 Publications Verification CAY-10572 hydrochloride	CDK Apoptosis	Cancer
PHA-767491 hydrochloride is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

HY-13231

CDK9-IN-1 1 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-141687

NSC 107512 1 Publications Verification	CDK Apoptosis	Cancer
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .

HY-100429

CAN508 1 Publications Verification	CDK	Cancer
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity .

HY-168518

*PROTAC CDK9* degrader-9**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-9 (compound 29) is a highly selective and efficient *CDK9* degrader based on PROTAC technology. PROTAC CDK9 degrader-9 can be used in anti-cancer research .

HY-139980

CDK9-IN-13	CDK	Cancer
CDK9-IN-13 (compound 38) is potent and selective *CDK9* inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .

HY-102039

CDK9-IN-8	CDK	Cancer
CDK9-IN-8 is a highly effective and selective *CDK9* inhibitor with an IC₅₀ of 12 nM.

HY-16462

CDK9-IN-2 5+ Cited Publications	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs .

HY-149964

*PROTAC CDK9* degrader-7**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-7 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome .

HY-115728

*PROTAC CDK9* degrader-4**	PROTACs	Cancer
PROTAC CDK9 degrader-4 is a highly potent and efficacious *CDK9* degrader for targeting transcription regulation.

HY-170978

*PROTAC CDK9* degrader-11**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC degrader for *CDK9* with DC₅₀ of 1.09 nM. PROTAC CDK9 degrader-11 exhibits cytotoxicity in multi small cell lung cancer cell with IC₅₀ of nanomolar levels. PROTAC CDK9 degrader-11 arrests cell cycle at G0/G1 phase, inhibits the cell invasion in DMS114 and DMS53 cell. PROTAC CDK9 degrader-11 exhibits antitumor efficacy in NCI-H446 xenograft mouse models .(Pink: ligand for target protein CDK9 ligand 3 (HY-170979); Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56 (HY-W247437))

HY-115714

CDK9-IN-12	CDK	Cancer
CDK9-IN-12 displays the optimal *CDK9* inhibitory activity with an IC₅₀ value of 5.41 nM.

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .

HY-176165

CDK9/EZH2-IN-1	CDK Histone Methyltransferase	Cancer
CDK9/EZH2-IN-1 (Compound D16) is a *CDK9/EZH2* dual-target inhibitor (IC₅₀: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC₅₀ values are 136.3, 171.3 and 315.7 nM, respectively) .

HY-12871C

Atuveciclib S-Enantiomer BAY-1143572 S-Enantiomer; (+)-Atuveciclib; (+)-BAY-1143572	CDK	Cancer
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective *CDK9* inhibitor, which inhibits *CDK9/CycT1* with an IC₅₀ of 16 nM.

HY-149962

*PROTAC CDK9* degrader-5**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-5 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-176451

CDK9 degrader-1	CDK	Cancer
CDK9 degrader-1 (Compound AZ-9) is a selective *CDK9* degrader (DC₅₀: 0.4073 µM). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuses with lysosomes to degrade CDK9 and its partner protein Cyclin T1 (DC₅₀: 1.215 µM). CDK9 degrader-1 induces caspase 3-mediated apoptosis. CDK9 degrader-1 has antitumor activity in a mouse HCT116 xenograft model .

HY-115729

*PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC CDK9 ligand-1 is a *CDK9* ligand that can be used in the synthesis of PROTACs.

HY-148521

*PROTAC FLT3/CDK9* degrader-1**	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-100950

ABC1183	GSK-3 CDK	Inflammation/Immunology Cancer
ABC1183 is an orally active selective dual GSK3 and *CDK9* inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .

HY-151984

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

HY-179023

CDK9-IN-45	CDK Apoptosis Reactive Oxygen Species (ROS) Caspase Bcl-2 Family c-Myc IAP	Cancer
CDK9-IN-45 (Compound B11) is a highly selective *CDK9* inhibitor with IC₅₀ values for CDK9 and CDK1 of 7.13 and 489.5 nM respectively. CDK9-IN-45 exhibits a potent inhibitory effect on colorectal cancer cells. CDK9-IN-45 induces cell apoptosis and leads to significant accumulation of ROS. CDK9-IN-45 activates Caspase-3, downregulates Mcl-1, XIAP, and c-Myc. CDK9-IN-45 can be used for research on colorectal cancer .

HY-168896

CDK9 autophagic degrader 1	CDK ATTECs	Cancer
CDK9 autophagic degrader 1 (Compound 28) is a ATTEC degrader that can be used to degrade *CDK9* and also affects the levels of the associated Cyclin T1. CDK9 autophagic degrader 1 shows over 80% *CDK9* inhibition rate at 100 nM . ( Pink: LC3B ligand (HY-168897); Black: linker (HY-W017758); Blue: target protein ligand (HY-10008); linker + target protein ligand (HY-168898))

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-178862

CDK9 ligand-Linker Conjugate	Target Protein Ligand-Linker Conjugates	Cancer
CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202 (HY-178861). dCDK9-202 is a potent CDK9 PROTAC degrader with anti-tumor activity .

HY-176736

CDK9-IN-40	CDK Apoptosis	Cancer
CDK9-IN-40 is a potent and orally active *CDK9* inhibitor with an IC₅₀ of 5.5 nM. CDK9-IN-40 shows high selectivity for *CDK9* versus CDK1, CDK2, CDK4, and CDK6, respectively. CDK9-IN-40 can arrest cell cycle, induce cell apoptosis and inhibit tumor growth. CDK9-IN-40 exhibits strong anti-cancer activity .

HY-157980

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

HY-178499

CDK9-IN-44	CDK c-Myc Bcl-2 Family	Neurological Disease Cancer
CDK9-IN-44 (Compound 7) is a selective *CDK9* inhibitor (IC₅₀=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders .

HY-156795

*PROTAC CDK9/CycT1 Degrader-2*	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-149963

*PROTAC CDK9* degrader-6**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-6 is a PROTAC targeting to *CDK9* sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively .

HY-149870

*PROTAC CDK9* degrader-8**	PROTACs CDK	Cancer
PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC₅₀ value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer .

HY-170979

CDK9 ligand 3	Ligands for Target Protein for PROTAC CDK	Cancer
CDK9 ligand 3 is the ligand for *CDK9* and can be used for synthesis of PROTAC degrader PROTAC CDK9 degrader-11 (HY-170978) .

HY-115729A

*(R)-PROTAC CDK9* ligand-1**	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

HY-147026

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

HY-RS02401

CDK9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
CDK9 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK9 Human Pre-designed siRNA Set A CDK9 Human Pre-designed siRNA Set A

HY-RS02402

Cdk9 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Mouse Pre-designed siRNA Set A Cdk9 Mouse Pre-designed siRNA Set A

HY-RS02403

Cdk9 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk9 Rat Pre-designed siRNA Set A Cdk9 Rat Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-P2559

CDK7/9 tide	CDK	Cancer
CDK7/9 tide is peptide substrate for CDK7 or CDK9 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-103248

Toyocamycin 5+ Cited Publications Vengicide	Infection Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	IRE1 Fungal Antibiotic Apoptosis CDK
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC₅₀ value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits *CDK9* with an IC₅₀ value of 79 nM .

HY-N1127

Tricin 5+ Cited Publications	Infection Flavonoids Classification of Application Fields Flavones Agrostidoideae Phenols Polyphenols Plants Disease Research Fields Triticum aestivum L. Source Classification	CMV
Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-N1127R

Tricin (Standard)	Structural Classification Flavonoids Flavones Agrostidoideae Phenols Polyphenols Plants Triticum aestivum L. Source Classification	Reference Standards CMV
Tricin (Standard) is the analytical standard of Tricin. This product is intended for research and analytical applications. Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-103248R

Toyocamycin (Standard) Vengicide (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards IRE1 Fungal Antibiotic Apoptosis CDK
DL-Aspartic acid (Standard) is the analytical standard of DL-Aspartic acid. This product is intended for research and analytical applications. DL-Aspartic acid (DL-Asp-OH) is a kind of biological materials or organic compounds that are widely used in life science research .

Recombinant Proteins Recommended:

CDK9

Species:	Human (7)
Tag:	His (2) Tag Free (3) GST (4) Flag (2)
Source:	Sf9 insect cells (7)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703558

	CDK9 Protein, Human (sf9, GST) CDC2L4; TAK	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9 Protein, Human (Sf9, GST) is the recombinant human-derived CDK9, expressed by Sf9 insect cells, with GST labeled tag. The total length of CDK9 Protein, Human (Sf9, GST) is 372 a.a..

HY-P701374

	CDK9-CCNK Heterodimer Protein, Human (sf9) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P701375

	CDK9-CCNK Heterodimer Protein, Human (Active, sf9, GST, FLAG) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNK Heterodimer Protein, Human (sf9, GST, FLAG) is a recombinant protein dimer complex containing human-derived CDK9-CCNK Heterodimer protein, expressed by sf9 insect cells , with N-Flag, N-GST labeled tag.

HY-P702689

	CDK9-CCNT1 Heterodimer Protein, Human (Active, sf9, GST, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT1 Heterodimer Protein, Human (sf9, GST, His) is the recombinant human-derived CDK9-CCNT1, expressed by Sf9 insect cells, with N-His, N-GST labeled tag.

HY-P702690

	CDK9-CCNT2 Heterodimer Protein, Human (Active, sf9, GST, Flag, His) CDK9; CCNK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-K	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT2 Heterodimer Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK9-CCNT2, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P701377

	CDK9-CCNT2 Heterodimer Protein, Human (sf9) CDK9; CCNT2; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T2; CycT2	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT2 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT2 Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P701376

	CDK9-CCNT1 Heterodimer Protein, Human (Active, sf9) CDK9; CCNT1; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit; Cyclin-T1; CycT1; Cyclin-T	Human	Sf9 insect cells
	The CDK9 protein plays a central role in transcriptional regulation, promoting the transition from ineffective to efficient elongation by phosphorylating POLR2A, SUPT5H, and RDBP. As part of the CDK9/cyclin-T complex, it participates in phosphorylation events affecting EP300, MYOD1, RPB1/POLR2A, AR, DSIF, and NELFE. CDK9-CCNT1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK9-CCNT1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N1127S

Tricin-d6
Tricin-d₆ is the deuterium labeled Tricin . Tricin is a natural flavonoid present in large amounts in Triticum aestivum. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7 .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

Host:	Mouse (1) Rabbit (3)
Reactivity:	Human (4) Rat (3) Mouse (3)
Application:	IHC-P (4) ICC/IF (4) IP (3) IHC-F (2) WB (4) ELISA (2)
Isotype:	IgG,Kappa (1) IgG (2)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87922

	Cdk9 Antibody (YA7607)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Cdk9 Antibody (YA7607) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Cdk9.

HY-P85098

	CDK9 Antibody (YA4790) CDK9; CDC2L4; TAK; Cyclin-dependent kinase 9; C-2K; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Serine/threonine-protein kinase PITALRE; Tat-associated kinase complex catalytic subunit	WB, IHC-P, ICC/IF, ELISA	Human
	CDK9 Antibody (YA4790) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CDK9.

HY-P80614

	CDK9 Antibody (YA509) TAK; C-2k; CTK1; CDC2L4; PITALRE	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	CDK9 Antibody (YA509) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK9.

HY-P80614A

	CDK9 Antibody (YA509)(PBS only) TAK; C-2k; CTK1; CDC2L4; PITALRE	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	CDK9 Antibody (YA509) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK9.